Precision Oncology in Breast Cancer Surgery

Ali Benjamin Abbasi,Vincent Wu,Julie E. Lang,Laura J. Esserman
DOI: https://doi.org/10.1016/j.soc.2023.12.011
IF: 2.402
2024-01-11
Surgical Oncology Clinics of North America
Abstract:• Breast cancer is a heterogeneous family of diseases that ranges from indolent to aggressive tumor biology. • Molecular testing biomarkers are useful to rationally select therapies for patients and to identify patients who carry deleterious gene mutations. • Response predictive subtypes may be used to guide treatment. • Appropriate de-escalation of cancer treatments based on disease response allows for avoidance of overtreatment. Breast cancer is a heterogeneous family of diseases that ranges from indolent to aggressive tumor biology. Molecular testing biomarkers are useful to rationally select therapies for patients and to identify patients who carry deleterious gene mutations. Response predictive subtypes may be used to guide treatment. Appropriate de-escalation of cancer treatments based on disease response allows for avoidance of overtreatment.
oncology,surgery
What problem does this paper attempt to address?